Welcome to AB Biosciences
Cart 0
OPG (HIS-FLAG-MYC-TAG)

OPG (HIS-FLAG-MYC-TAG)

$ 690.00

Osteoprotegerin (OPG), also known as OCIF (osteoclastogenesis inhibitory factor), is a basic glycoprotein comprising 401 amino acid residues arranged into 7 structural domains, forms dimer via the penultimate Cys400 residues, and is one of the only two soluble decoy receptors within the TNFR superfamily.

Interacting protein(s): TRAIL (P7008F), RANKL
Related products: TNF-Receptor Superfamily

Read all details below including Quick Specs.

** Please note: For orders over 1 mg, please inquire here

Quick Specs

Species: Human
Catalog No.: P7019T
Synonym: TNFRSF11B, MGC29565, OCIF, TR1
Tag: His-FLAG tag at the N-terminus and Myc tag at the C-terminus
GenBank accession: NM_002546
SwissPro accession: O00300
Expression Host: 293T
Construction: His-FLAG-Human OPG (F24-K194)-Myc
MW (calculated): 23,422 daltons
MW (SDS-PAGE): 25 Kd
Abs 0.1% (= 1 mg/ml): 1.090
Purity: 95%

Description

Osteoprotegerin (OPG), also known as OCIF (osteoclastogenesis inhibitory factor), is a basic glycoprotein comprising 401 amino acid residues arranged into 7 structural domains, forms dimer via the penultimate Cys400 residues, and is one of the only two soluble decoy receptors within the TNFR superfamily. OPG has two ligands, the RANKL (receptor activator of nuclear factor kappa B ligand) TRAIL (tumor necrosis factor-related apoptosis-inducing ligand).

OPG binding to RANKL on osteoblast/stromal cells, blocks the RANKL-RANK ligand interaction between osteoblast/stromal cells and osteoclast precursors. This has the effect of inhibiting the differentiation of the osteoclast precursor into a mature osteoclast. Mice over expressing OPG exhibit nonlethal osteopetrosis, coincident with a decrease in later stages of osteoclast differentiation. These same effects are observed upon administration of recombinant OPG into normal mice.

Space shuttle flight STS-108 in 2001 tested the effects of osteoprotegerin on mice in microgravity, finding that it did prevent increase in resorption and maintained mineralization. Osteoprotegerin has been used experimentally to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases.

Amino Acid Sequence.

References

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309–319
2. Emery JG, McDonnell P, Burke MB, et al. (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273: 14363–14367
3. Bateman TA, Countryman S (2002). Osteoprotegerin and bone loss associated with spaceflight. Drug Discov. Today 7: 456–457.


Share this Product


More from this collection